Back to Agenda
[V3-S5] Chance and Challenge to Maximize Product Value - Key Findings from Collaboration Between Medicine Development Division and Medical Affairs Division -
Session Chair(s)
Hiroshi Aino, MD, PhD
Senior Medical Officer
Sumitomo Dainippon Pharma Co., Ltd., Japan
Aiming to maximize product value seamlessly from the medicine development stage to launch stage, some pharmaceutical companies are creating or implementing key strategies such as development strategy, publication strategy, KOL engagement strategy etc with more closer partnership between medicine development related division and medical affairs division. Also, Medical Science Liaisons (MSLs) play key role which collects unmet medical needs from healthcare professionals and their contribution would be crucial one to find new development opportunity or to generate valuable evidence. In this session, presenters will provide some examples of collaboration in each company and we are going to discuss how medicine development division and medical affairs division should collaborate to maximize product value.
Speaker(s)
Chance and Challenge to Maximize Product Value
Yasuyuki Katayama, MD, PhD
Pfizer Japan Inc., Japan
Corporate Officer, Country Medical Director and Head of Medical Japan
Chance and Challenge to Maximize Product Value
Sotaro Enatsu, MD, PhD
Eli Lilly Japan K.K., Japan
Collaboration between Medical Information and Clinical Pharmacology
Manabu Murakami, PhD, MS, RPh
Astellas Pharma Inc., Japan
Vice President, Clinical Pharmacology Development
Kosuke Kozaiwa, MD
GlaxoSmithKline K.K., Japan
VP & Vice Head, Japan Development
Have an account?